Skip to main content
main-content

14-06-2020 | Haematology | Video

EHA25 | Frontline venetoclax plus low-dose cytarabine supported for older patients with AML

Andrew Wei presents updated findings from the phase 3 VIALE-C acute myeloid leukaemia trial, discussing how these and the VIALE-A data cement the role of venetoclax as a first-line option for older patients and those ineligible for intensive chemotherapy (7:41).

Funding for independent interviews at EHA25 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits